Phathom Pharmaceuticals, Inc. - Common Stock (PHAT)

Phathom Pharmaceuticals (NASDAQ:PHAT) reported second-quarter 2026 revenue growth of 88% year over year and said it achieved positive operating profit excluding stock-based compensation for the first time in its history, reaching the milestone one quarter ahead of its prior plan. The company report

Phathom (PHAT) Q1 2026 Earnings Transcript

Phathom (PHAT) Q4 2025 Earnings Call Transcript

Phathom Pharmaceuticals (NASDAQ: PHAT) reported Q4 sales of $57-$58 million, updated FY2025 revenue guidance to $174.5-$175.5 million.

PHAT stock aligns with the Minervini growth strategy, showing a strong technical uptrend and explosive 460% revenue growth, making it a high-potential momentum candidate.

Discover a powerful stock-picking strategy combining Minervini's Trend Template with High Growth Momentum to find high-potential stocks like PHAT.

Phathom Pharma's Q3 2025 earnings beat expectations. Revenue hit $49.5M, and its EPS loss narrowed to $0.15. The company also raised its full-year 2025 revenue guidance.

Phathom Pharmaceuticals (PHAT) beats Q2 revenue and EPS estimates, driven by strong VOQUEZNA adoption. Shares rise 6.2% premarket as company narrows losses and raises full-year guidance.

Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) shares are trading lower Friday after the company announced a major regulatory win.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.

Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.